摘要
维生素D缺乏和机能不全与不断增加的癌症、自身免疫疾病、炎症、感染、心血管疾病和代谢疾病以及骨和矿物质紊乱都有关联。维生素D受体(VDR)作为核受体超家族的成员,是维生素D一种活性形式的受体,1α,25-二羟基维生素D3[1,25(OH)2D3],并且介导维生素D调节特异性靶点基因表达。由长细菌昌盛的二级胆汁酸石胆酸是另一种天然的VDR配体。已提出VDR信号参与肠细胞(包括免疫与上皮细胞)与肠道微生物群落之间的相互交流。除了维生素D状态的流行病学研究外,全基因组分析和细胞、动物实验已经显示VDR参与预防炎性肠道疾病(IBD)和结肠癌(CRC)。小鼠中的VDR缺失在实验模型中夸大了结肠炎和结肠肿瘤的发生,并且使用合成维生素D类似物治疗的小鼠改善了这些疾病的病理变化。几种VDR配体在增加血清钙水平活性较低,显示出比天然激素1,25(OH)2D3更高的治疗效果。VDR在肠内稳态和预防IBD和CRC起着重要的作用。减少或者不减少钙化活性的CDR配体的开发对扩大CDR靶向治疗的临床应用是有必要的。
关键词: 维生素D受体,炎症肠道疾病,结肠癌,维生素D类似物,胆汁酸,高钙血症,选择性维生素D受体调节剂
Current Medicinal Chemistry
Title:Control of Inflammatory Bowel Disease and Colorectal Cancer by Synthetic Vitamin D Receptor Ligands
Volume: 24 Issue: 9
关键词: 维生素D受体,炎症肠道疾病,结肠癌,维生素D类似物,胆汁酸,高钙血症,选择性维生素D受体调节剂
摘要: Vitamin D deficiency and insufficiency are associated with an increased risk of cancer, autoimmune disease, inflammation, infection, cardiovascular disease and metabolic disease, as well as bone and mineral disorders. The vitamin D receptor (VDR), a member of the nuclear receptor superfamily, is a receptor for the active form of vitamin D, 1α,25-dihydroxyvitamin D3 [1,25(OH)2D3], and mediates vitamin D regulation of specific target gene expression. The secondary bile acid lithocholic acid, which is produced by intestinal bacteria, is another natural VDR ligand. VDR signaling has been suggested to be involved in reciprocal communication between intestinal cells, including immune and epithelial cells, and intestinal microflora. In addition to epidemiological studies on vitamin D status, genome-wide analyses and cellular and animal experiments have shown that VDR is involved in the prevention of inflammatory bowel disease (IBD) and colorectal cancer (CRC). VDR deletion in mice exaggerates colitis and colon tumorigenesis in experimental models, and treatment of mice with synthetic vitamin D analogues ameliorates pathological changes in these diseases. Several VDR ligands are less active in increasing serum calcium levels, showing higher therapeutic efficiency than the natural hormone 1,25(OH)2D3. VDR plays a role in intestinal homeostasis and in protection against IBD and CRC. The development of VDR ligands with reduced or no calcemic activity will be necessary to expand clinical application of VDRtargeting therapy.
Export Options
About this article
Cite this article as:
Control of Inflammatory Bowel Disease and Colorectal Cancer by Synthetic Vitamin D Receptor Ligands, Current Medicinal Chemistry 2017; 24 (9) . https://dx.doi.org/10.2174/0929867323666161202145509
DOI https://dx.doi.org/10.2174/0929867323666161202145509 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Role of Mucins in Epithelial to Mesenchymal Transition
Current Cancer Drug Targets Patent Selections:
Recent Patents on Regenerative Medicine Aflibercept: A Novel VEGF Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Tumors
Mini-Reviews in Medicinal Chemistry Significant Role of MUC1 in Development of Resistance to Currently Existing Anti-cancer Therapeutic Agents
Current Cancer Drug Targets Innovation in Contrast Agents for Magnetic Resonance Imaging
Current Medical Imaging Lipid-based Nanoplatforms in Cancer Therapy: Recent Advances and Applications
Current Cancer Drug Targets The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Functionalized Nanocarriers for Enhanced Bioactive Delivery to Squamous Cell Carcinomas: Targeting Approaches and Related Biopharmaceutical Aspects
Current Pharmaceutical Design Diagnostic and Therapeutic Applications of Recombinant Antibodies:Targeting the Extra-Domain B of Fibronectin, A Marker of Tumor Angiogenesis
Current Pharmaceutical Design Effect of Substituted Benzimidazoles and Somatostatin Analogs on the Vitality of Tumor Cell Lines and on the Oxidative Burst of Phagocytes
Letters in Drug Design & Discovery Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
Anti-Cancer Agents in Medicinal Chemistry Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Epigenetic Targeting of Platinum Resistant Testicular Cancer
Current Cancer Drug Targets Anti-VEGF Therapy for Retinal Vein Occlusions
Current Drug Targets Tumor Necrosis Factor-α, a Regulator and Therapeutic Agent on Breast Cancer
Current Pharmaceutical Biotechnology Prospects of miRNA-Based Therapy for Pancreatic Cancer
Current Drug Targets Traditional Uses, Therapeutic Effects and Recent Advances of Curcumin: A Mini-Review
Mini-Reviews in Medicinal Chemistry Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology miR-21, An Oncogenic Target miRNA for Cancer Therapy: Molecular Mechanisms and Recent Advancements in Chemo and Radio-resistance
Current Gene Therapy